Clear answers, from strategy to study delivery.
Whether you are planning a clinical study, looking for specialist support or already working with us, here are answers to some of the questions we are asked most often.
Clarenta is a European clinical development partner helping biotech and pharmaceutical companies navigate complex development decisions. We connect strategy, regulatory expertise, early-phase capabilities and clinical delivery, with a particular focus on early development.
No. Clarenta is the new unified identity bringing together the people, experience and capabilities of Comac Medical and ILife Consulting. There has been no change of ownership.
Our organisation has evolved, particularly through the integration of ILife Consulting and its specialist consulting and early-phase expertise. Clarenta gives our combined teams one identity and reflects our clearer focus on helping clients navigate clinical development.
ILife Consulting joined Comac Medical Group in May 2025 and is now part of Clarenta. Its development consulting and early-phase expertise, particularly in oncology, strengthen the support we provide before and during clinical development.
Our main focus is early development, from non-clinical strategy and regulatory planning through Phase I/IIa. We also provide clinical operations for selected Phase II and Phase III studies when our expertise and European reach are the right fit.
Our capabilities include development strategy and consulting, regulatory affairs, early-phase clinical research, clinical operations, biometrics, medical affairs, quality and pharmacovigilance.
Our FDA- and EMA-inspected Early Phase Unit in Sofia, Bulgaria, is dedicated to Phase I clinical research. It combines experienced medical and operational teams with the facilities needed to conduct first-in-human and other complex early-phase studies
Yes. Involving our team early allows us to assess the development strategy, regulatory pathway, study design, feasibility and operational risks before they become more difficult to address.
We have experience across a broad range of therapeutic areas, with established expertise in oncology and onco-haematology, rare diseases, neurology and psychiatry, respiratory diseases, dermatology and gastroenterology.
Our colleagues are based across more than 20 countries in Europe and neighbouring markets. This internal presence is complemented by an established network of clinical professionals and partners, allowing us to support studies in additional European markets.
We work with biotech companies, small and mid-sized pharmaceutical companies, selected larger pharmaceutical organisations and CRO partners. Our model is particularly well suited to teams that need experienced support, flexibility and direct access to senior expertise.
Both. We can provide a specific service or bring together an integrated team across several parts of a development programme. The model is built around what the project genuinely needs.
We connect what often sits apart: development strategy, regulatory expertise and clinical delivery. This means practical advice shaped by operational reality, supported by experienced teams who remain close to the project.
Yes. We can work as part of an existing delivery model, providing specific expertise, Early Phase Unit capabilities or support in European markets. Roles and responsibilities are agreed clearly from the beginning.